Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors-Reference-Cited by-同舟云学术

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors

Published:2016-04-25 Issue:6 Volume:48 Page:600-606
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Kim Jaegil,Mouw Kent W,Polak Paz,Braunstein Lior Z,Kamburov Atanas,Tiao Grace,Kwiatkowski David J,Rosenberg Jonathan E,Van Allen Eliezer M,D'Andrea Alan D,Getz Gad

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3557.pdf

Reference48 articles.

1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

2. Dietlein, F., Thelen, L. & Reinhardt, H.C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 30, 326–339 (2014).

3. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17–37 (2013).

4. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

5. Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy;Cancer Immunology, Immunotherapy;2024-09-05

2. The theory of massively repeated evolution and full identifications of Cancer Driving Nucleotides (CDNs);2024-09-03

3. The theory of massively repeated evolution and full identifications of Cancer Driving Nucleotides (CDNs);2024-09-03

4. Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features;Cancer Research Communications;2024-09-01

5. Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review;Cancers;2024-09-01